PCM
Penserra Capital Management Portfolio holdings
AUM
$7.17B
1-Year Return
49.58%
This Quarter Return
+9.42%
1 Year Return
+49.58%
3 Year Return
+118.16%
5 Year Return
+229.83%
10 Year Return
–
AUM
$5.41B
AUM Growth
+$1.18B
(+28%)
Cap. Flow
+$972M
Cap. Flow
% of AUM
17.96%
Top 10 Holdings %
Top 10 Hldgs %
20.49%
Holding
1,158
New
152
Increased
697
Reduced
246
Closed
52
Top Buys
| 1 |
Alibaba
BABA
|
$59.8M |
| 2 |
JD.com
JD
|
$41.3M |
| 3 |
Mercado Libre
MELI
|
$35.1M |
| 4 |
NetEase
NTES
|
$34.7M |
| 5 |
KE Holdings
BEKE
|
$19.5M |
Top Sells
| 1 |
Futu Holdings
FUTU
|
$27.8M |
| 2 |
Trip.com Group
TCOM
|
$21.9M |
| 3 |
AOD
abrdn Total Dynamic Dividend Fund
AOD
|
$12.1M |
| 4 |
Gabelli Dividend & Income Trust
GDV
|
$12M |
| 5 |
EFR
Eaton Vance Senior Floating-Rate Fund
EFR
|
$11.2M |
Sector Composition
| 1 | Consumer Discretionary | 33.74% |
| 2 | Technology | 22.72% |
| 3 | Communication Services | 13.35% |
| 4 | Industrials | 4.85% |
| 5 | Real Estate | 4.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
926
Cboe Global Markets
CBOE
$24.3B
| $26K | ﹤0.01% |
269
+40
| +17% | +$3.87K |
|
927
Iron Mountain
IRM
$27.2B
| $26K | ﹤0.01% |
721
+117
| +19% | +$4.22K |
|
|
AVLR
928
DELISTED
Avalara, Inc.
AVLR
| $26K | ﹤0.01% |
202
+32
| +19% | +$4.12K |
|
929
Comerica
CMA
$8.85B
| $25K | ﹤0.01% |
350
+60
| +21% | +$4.29K |
|
930
Mersana Therapeutics
MRSN
$34M
| $25K | ﹤0.01% |
63
| – | – |
|
931
Protagonist Therapeutics
PTGX
$3.77B
| $25K | ﹤0.01% |
970
+90
| +10% | +$2.32K |
|
932
Repare Therapeutics
RPTX
$72.6M
| $25K | ﹤0.01% |
830
-15
| -2% | -$452 |
|
933
W.R. Berkley
WRB
$27.3B
| $25K | ﹤0.01% |
754
+108
| +17% | +$3.58K |
|
934
Western Union
WU
$2.86B
| $25K | ﹤0.01% |
1,025
+160
| +18% | +$3.9K |
|
|
CNST
935
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $25K | ﹤0.01% |
1,085
-5
| -0.5% | -$115 |
|
936
Citigroup
C
$176B
| $24K | ﹤0.01% |
333
+222
| +200% | +$16K |
|
937
Coherus Oncology, Inc. Common Stock
CHRS
$150M
| $24K | ﹤0.01% |
1,655
| – | – |
|
938
Everest Group
EG
$14.3B
| $24K | ﹤0.01% |
100
+16
| +19% | +$3.84K |
|
939
Henry Schein
HSIC
$8.42B
| $24K | ﹤0.01% |
355
+56
| +19% | +$3.79K |
|
940
Nordson
NDSN
$12.6B
| $24K | ﹤0.01% |
125
+16
| +15% | +$3.07K |
|
941
Nkarta
NKTX
$161M
| $24K | ﹤0.01% |
740
-10
| -1% | -$324 |
|
942
Omeros
OMER
$284M
| $24K | ﹤0.01% |
1,390
-25
| -2% | -$432 |
|
943
Personalis
PSNL
$465M
| $24K | ﹤0.01% |
990
+95
| +11% | +$2.3K |
|
944
Quince Therapeutics
QNCX
$86.5M
| $24K | ﹤0.01% |
670
-5
| -0.7% | -$179 |
|
945
Universal Health Services
UHS
$12.1B
| $24K | ﹤0.01% |
182
+24
| +15% | +$3.17K |
|
|
ZGNX
946
DELISTED
Zogenix, Inc.
ZGNX
| $24K | ﹤0.01% |
1,255
-20
| -2% | -$382 |
|
947
Syndax Pharmaceuticals
SNDX
$1.47B
| $23K | ﹤0.01% |
1,065
+125
| +13% | +$2.7K |
|
948
Sutro Biopharma
STRO
$89.9M
| $23K | ﹤0.01% |
1,015
+115
| +13% | +$2.61K |
|
949
Annexon
ANNX
$238M
| $23K | ﹤0.01% |
860
-25
| -3% | -$669 |
|
950
Arcturus Therapeutics
ARCT
$485M
| $23K | ﹤0.01% |
580
+20
| +4% | +$793 |
|